This report was first published by Endpoints News. To see the original version, click here
Innovent Biologics’ ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps.
The Phase 3 win will also sharpen scrutiny on Takeda, which signed a deal worth up to $11.4 billion with Innovent in October 2025 to secure rights to several Innovent drugs, including arcotatug tavatecan, outside of China and nearby markets.
您已阅读15%（507字），剩余85%（2984字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。